- Conditions
- Hemophilia A
- Interventions
- efanesoctocog alfa
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemophilia A
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Not listed
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • Gainesville, Florida + 12 more
- Conditions
- Hemophilia A
- Interventions
- Efanesoctocog Alfa BIVV001
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more
- Conditions
- Von Willebrand's Disease (VWD)
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania
- Conditions
- Hemophilia A
- Interventions
- efanesoctocog alfa (BIVV001)
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
- Conditions
- Factor VIII Deficiency
- Interventions
- efanesoctocog alfa (BIVV001)
- Biological
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more
- Conditions
- Factor VIII Deficiency
- Interventions
- Efanesoctocog alfa
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 1 more